GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vectorite Biomedical 4170.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

10.95

-0.45%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Vectorite Biomedical

Its shares trade on Taipei Exchange under the ticker 4170.TWO. It has been listed since 28 December 2023. In the fiscal year to 31 December 2025, it reported revenue of TWD 61.4m and net income of TWD 96.2m. At that date it held total assets of TWD 509.6m and shareholders' equity of TWD 484.7m.

Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens”. The company is headquartered in Taipei, New Taipei. The company went IPO on 2023-12-28. Products include dendritic cell (DC) vaccines, and natural killer (NK) cell preparations for cancer treatment. The firm also provides immune cell collection, processing and storage services, cell preparation safety testing services, anti-cancer immunity testing services, original design manufacturer (ODM)/ contract development and manufacturing organization (CDMO) services, related medical consulting services, and laboratory quality management services. Products are mainly sold domestically.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
28 Dec 2023

Leadership

Pay as last reported

  • Mr. Suozhu ZhangChairman of the Board, since 2019
  • Mr. Mingchang OuGeneral Manager
  • Huijing YouHead of Finance & Accounting
  • Chang'en CaiDirector
  • Mr. Shixing CaiDirector
  • Xiangyue MengDirector
  • Borong LaiIndependent Director
  • Mr. Jianming TangIndependent Director
  • Zongxian YangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Xinpin Biomedical Group's DC vaccines and NK cell preparations are key cancer treatment products in Taiwan.
  • Taipei headquarters supports domestic market focus with strong local regulatory compliance.
  • Xinpin Biomedical Group offers comprehensive immune cell services including storage and testing.

Weaknesses

  • Limited international market presence due to domestic sales focus in Taiwan.
  • Dependence on Taiwan's domestic healthcare sector for revenue generation.
  • No international expansion plans mentioned for 2023-2024 period.

Opportunities

  • Growing demand for advanced cancer treatments in Taiwan's Health Care sector.
  • Potential for expanding ODM/CDMO services within Taiwan's biotechnology industry.
  • Increasing focus on immune cell therapies in the Health Care industry.

Threats

  • Regulatory changes in Taiwan's Health Care sector could impact operations.
  • Competition from domestic biotechnology firms in Taiwan's market.
  • Economic downturn in Taiwan might reduce healthcare spending.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.